Utilizing HER2 with Immune Agents: CAR-T Approach in Advanced Hematologic Cancers & Refractory Solid Tumors
Time: 12:30 pm
day: Day One
Details:
• Discussing patient selection and response biomarkers
• Challenges of clinical translation
• Latest data & future directions